Kairos Pharma, LTD. (KAPA): Submission of Matters to a Vote of Security Holders
Kairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001962011 0001962011 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor
How this was made
The 30-second read
Why it matters
Voting outcomes include: (1) election of four directors, (2) ratification of independent auditors, (3) approval of a certificate amendment authorizing a reverse stock split at a board-determined ratio between 1:3 and 1:250, (4) advisory approval of executive compensation, and (5) approval of equity incentive plan amendments adding 5,000,000 shares plus an evergreen 5% annual increase for ten years.
Market read
This is a governance/capital-structure update: reverse split authorization and equity plan share refresh can affect trading, but the filing lacks execution specifics (exact ratio and implementation schedule).
What to watch
Equity plan “evergreen” increases can be a longer-term overhang, but the filing provides no new financing terms or dilution estimates—watch for subsequent board action/prospectus details.
Background
The company’s 8-K (Item 5.07) summarizes results from its June 29, 2026 annual stockholders meeting.
Ticker impact
Kairos Pharma filed an 8-K reporting annual meeting voting results, including approval of a reverse stock split and equity plan amendments.
Likely limited immediate impact; any price effect would depend on how/when the board implements the authorized reverse split ratio.
The filing is a primary SEC disclosure of voting outcomes, but it does not provide implementation details (exact split ratio/timing) beyond board discretion.
Market effects
Microcap/small-cap biotech governance actions (reverse split authorization, equity plan refresh) can influence sentiment toward similar pre-commercial issuers.
No clear regional spillover beyond US-listed small-cap biotech.
Minimal; filing is company-specific and not tied to global regulatory or clinical milestones.
Counterpoint
The reverse split is only authorized with a wide ratio range and board discretion; traders may overreact versus the actual likelihood/timing of implementation.
Key entities
- companyKairos Pharma Ltd.
US-listed biotech issuer (NYSE American) whose shareholder votes were reported in the 8-K.
- auditorWeinberg & Company, P.A.
Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.
